Aeterna Zentaris Engages Advisors and Provides Update to Shareholders


As previously announced, the Strategic Review Committee has been tasked to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing business plan and/or considering and recommending changes to the Company's management and governance. Both selected firms have well regarded reputations in the pharmaceutical, biotechnology and life sciences sectors.



from Biotech News